A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 720 participants.

Also called NCT07253584

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 720 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07253584
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07253584. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-19 (actual); primary completion 2025-06-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia
Condition
Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
Intervention (Drug)
SAL003 140 mg
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07253584
Content hash
31031fa9b50d11985c0c72febd9765e296b81ae12146d670967d56e26b86b44b